YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This study aimed to clarify the potential role of Yes1-asso...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ling-Chen, Chen, Xie-Wan, Fang, Ling, Jian, Chun-Li, Yu, Yong-Xin, Liao, Xing-Yun, Sun, Jian-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307059/
https://www.ncbi.nlm.nih.gov/pubmed/37388902
http://dx.doi.org/10.1155/2023/4689004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307059/
https://www.ncbi.nlm.nih.gov/pubmed/37388902
http://dx.doi.org/10.1155/2023/4689004

Ejemplares similares